Insider Selling: Outset Medical, Inc. (NASDAQ:OM) CFO Sells $10,401.04 in Stock

Outset Medical, Inc. (NASDAQ:OM) CFO Nabeel Ahmed sold 584 shares of the firm’s stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $17.81, for a total value of $10,401.04. Following the completion of the sale, the chief financial officer now directly owns 16,096 shares of the company’s stock, valued at approximately $286,669.76. This represents a 3.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Outset Medical Stock Performance

Shares of OM stock opened at $19.50 on Monday. The business has a fifty day moving average of $11.57 and a 200 day moving average of $12.84. Outset Medical, Inc. has a 1 year low of $5.85 and a 1 year high of $72.60. The company has a debt-to-equity ratio of 4.12, a current ratio of 6.49 and a quick ratio of 5.04. The firm has a market capitalization of $70.10 million, a price-to-earnings ratio of -7.86 and a beta of 1.90.

Outset Medical (NASDAQ:OM) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($3.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($2.69). Outset Medical had a negative return on equity of 175.64% and a negative net margin of 112.57%. The firm had revenue of $29.75 million during the quarter, compared to analysts’ expectations of $27.81 million. As a group, research analysts expect that Outset Medical, Inc. will post -1.99 earnings per share for the current year.

Hedge Funds Weigh In On Outset Medical

Several hedge funds and other institutional investors have recently bought and sold shares of OM. Two Sigma Securities LLC lifted its stake in Outset Medical by 190.0% during the 4th quarter. Two Sigma Securities LLC now owns 42,477 shares of the company’s stock valued at $47,000 after acquiring an additional 27,830 shares during the period. XTX Topco Ltd acquired a new stake in shares of Outset Medical in the fourth quarter worth $50,000. TD Asset Management Inc purchased a new position in shares of Outset Medical during the first quarter worth $589,000. Squarepoint Ops LLC acquired a new position in Outset Medical during the fourth quarter valued at $174,000. Finally, Parkman Healthcare Partners LLC purchased a new stake in Outset Medical in the first quarter valued at $2,556,000.

Analyst Upgrades and Downgrades

Several brokerages recently commented on OM. Royal Bank of Canada increased their price objective on shares of Outset Medical from $12.00 to $14.00 and gave the company a “sector perform” rating in a research report on Thursday, May 8th. Stifel Nicolaus set a $15.00 price target on shares of Outset Medical in a research note on Friday, March 21st.

Outset Medical Company Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.